Company
Headquarters: Dijon, France
Employees: 85
CEO: Mr. Patrick Alexandre
€146.8 Million
EUR as of July 1, 2023
US$160.2 Million
Company | Market Cap (USD) |
---|---|
![]() |
$116.08 B |
![]() |
$84.47 B |
![]() |
$73.65 B |
![]() |
$40.22 B |
![]() |
$39.96 B |
Company | Market Cap (USD) |
---|---|
![]() |
$428.70 B |
![]() |
$417.05 B |
![]() |
$412.24 B |
![]() |
$329.83 B |
![]() |
$275.82 B |
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Unlock the Power of Financial AI:
Try Disfold AI Free for 7 Days!
Crossject SA has the following listings and related stock indices.
Stock: Euronext: ALCJ wb_incandescent
Stock: FSX: 74C wb_incandescent